Animal Life Sciences has licensed multiple drug technologies developed at the M.D. Anderson Cancer Center for the following diseases in animals:

1

Advanced chemotherapies for the treatment of leukemias and brain tumors

2

Cell signaling modulators and inhibitors of glycolysis for the treatment of a wide range of tumors

3

Topical treatments for a wide range of cancerous and noncancerous inflammatory skin conditions

OUR DRUG PIPELINE

Current Stages of Development and Testing

DRUG PORTFOLIO

10 Drugs in Development Across 5 Different Indications

Alongside direct investment of $60 million, over $43 million of grant funding (total of $103 million USD) has gone towards the development of our robust drug development pipeline.

brain cancer

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

brain cancer

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

brain cancer

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

melanoma

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

melanoma

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

Leukemia

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

Multiple Tumors

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

Multiple Tumors

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

Multiple Tumors

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science

Pancreatic Cancer

  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science
  • Targeting the treatment of spontaneous gliomas
  • This technology was developed at Wake Forest University and licensed through a collaboration with WPD Pharmaceuticals. WPD101 has received a $10mm grant from the country of Poland
  • Put brief detail on science